Acambis PLC’s Universal Influenza Vaccine Enters Phase 1 Trial

Cambridge, UK and Cambridge, Massachusetts – 17 July 2007 – Acambis plc (Acambis) (LSE: ACM), a leading vaccines company, announces that it has initiated a Phase 1 clinical trial of its universal influenza vaccine candidate, ACAM-FLU-A.
MORE ON THIS TOPIC